CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
Status:
Not yet recruiting
Trial end date:
2025-12-15
Target enrollment:
Participant gender:
Summary
This phase I trial studies the effects of CD-19 directed chimeric antigen receptor (CAR)-T
cell therapy for the treatment of patients with B cell malignancies that have come back
(recurrent) or have not responded to treatment (refractory). CD-19 CAR-T cells use some of a
patient's own immune cells, called T cells, to kill cancer. T cells fight infections and, in
some cases, can also kill cancer cells. Some T cells are removed from the blood, and then
laboratory, researchers will put a new gene into the T cells. This gene allows the T cells to
recognize and possibly treat cancer. The new modified T cells are called the IC19/1563
treatment. IC19/1563 may help treat patients with relapsed/refractory B cell malignancies.